Supernus Pharmaceuticals (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 67,132 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $53.11, for a total transaction of $3,565,380.52. Following the completion of the sale, the vice president now owns 32,500 shares of the company’s stock, valued at $1,726,075. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Supernus Pharmaceuticals opened at $58.35 on Thursday, according to MarketBeat.com. Supernus Pharmaceuticals has a one year low of $57.45 and a one year high of $58.55. The company has a market cap of $2.96 billion, a price-to-earnings ratio of 46.31 and a beta of 1.14. The company has a debt-to-equity ratio of 0.90, a current ratio of 4.90 and a quick ratio of 4.74.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.26 by $0.18. Supernus Pharmaceuticals had a net margin of 21.89% and a return on equity of 30.18%. The business had revenue of $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. sell-side analysts anticipate that Supernus Pharmaceuticals will post 1.91 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 12th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 5th. Berenberg Bank assumed coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, February 1st. They issued a “buy” rating and a $66.00 price target for the company. Finally, B. Riley reiterated a “buy” rating and issued a $54.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $51.36.

A number of institutional investors and hedge funds have recently made changes to their positions in SUPN. JPMorgan Chase & Co. raised its position in Supernus Pharmaceuticals by 166.0% during the first quarter. JPMorgan Chase & Co. now owns 461,586 shares of the specialty pharmaceutical company’s stock valued at $21,140,000 after purchasing an additional 288,059 shares in the last quarter. Stephens Investment Management Group LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $7,316,000. BlackRock Inc. raised its position in Supernus Pharmaceuticals by 2.5% during the first quarter. BlackRock Inc. now owns 7,071,947 shares of the specialty pharmaceutical company’s stock valued at $323,898,000 after purchasing an additional 169,717 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $7,761,000. Finally, Wells Fargo & Company MN raised its position in Supernus Pharmaceuticals by 18.6% during the first quarter. Wells Fargo & Company MN now owns 896,110 shares of the specialty pharmaceutical company’s stock valued at $41,041,000 after purchasing an additional 140,688 shares in the last quarter. Institutional investors and hedge funds own 95.47% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.